This study is looking at a medicine called CHF6001 (Tanimilast) for people with COPD and chronic bronchitis. COPD stands for Chronic Obstructive Pulmonary Disease, a lung condition that makes it hard to breathe. The study will last for 52 weeks, or about a year, and will compare the effects of the medicine to a placebo, which is a harmless pill that doesn’t contain the medicine.
To be part of the study, you must be 40 or older, have COPD and chronic bronchitis, and be a current or former smoker. You also need to have been on a regular treatment for at least a year. You cannot join if you have asthma, certain other health issues, or have been on specific medications recently.
- The study lasts for about 1 year.
- Participants may receive a new medicine or a placebo.
- Some health conditions or recent treatments may exclude you from participating.